High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer

Sawada,Ryoichi; Arai,Yoshinori; Sagawa,Yukiko; Nagata,Yusuke; Nishimura,Takashi; Noguchi,Masaaki; Amano,Katsushi; Arihiro,Seiji; Saruta,Masayuki; Homma,Sadamu

doi:10.3892/or.2019.7304

High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer

Authors:
- Ryoichi Sawada
- Yoshinori Arai
- Yukiko Sagawa
- Yusuke Nagata
- Takashi Nishimura
- Masaaki Noguchi
- Katsushi Amano
- Seiji Arihiro
- Masayuki Saruta
- Sadamu Homma
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan, Division of Oncology, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo 105‑8461, Japan
Published online on: September 6, 2019 https://doi.org/10.3892/or.2019.7304
Pages: 2057-2064

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The interaction between tumor necrosis factor receptor superfamily, member 4 (OX40) on T cells and the OX40 ligand (OX40L) on antigen‑presenting cells (APCs) is a pivotal step for T‑cell activation and the promotion of antitumor immunity. However, it is hypothesized that soluble OX40 (sOX40) in blood suppresses T‑cell activation by blocking the OX40/OX40L interaction. In the present study, the association between blood sOX40 levels and the clinical characteristics of advanced colorectal cancer (CRC) patients was investigated. Blood was collected from 22 patients with advanced CRC. Blood sOX40 levels were determined by enzyme‑linked immunosorbent assay (ELISA). Messenger RNA (mRNA) expression encoding OX40 or cytokines was analyzed by quantitative RT‑PCR. Blood sOX40 levels were positively correlated with the blood levels of carbohydrate antigen (CA) 19‑9, carcinoembryonic antigen (CEA), C‑reactive protein (CRP) and soluble programmed cell death ligand‑1 (PD‑L1) in patients but negatively correlated with the blood levels of albumin. Blood sOX40 levels were not correlated with the mRNA expression of interferon (IFN)‑gamma, interleukin (IL)‑6, IL‑10 and IL‑4 in the peripheral blood mononuclear cells (PBMCs) of the patients and were not correlated with the frequency of programmed cell death‑1 (PD‑1) expressing CD4+, CD8+ and CD56+ cells. Notably, according to both univariate and multivariate analyses, high blood sOX40 levels were significantly correlated with a reduced survival time in patients. Although activated Jurkat cells (a human T cell line) exhibited an upregulation of sOX40 production and OX40 mRNA expression, the OX40 mRNA expression of the PBMCs of patients was not correlated with blood sOX40 levels. High blood levels of sOX40 were correlated with a reduced survival time in patients with advanced CRC, possibly associated with the suppression of antitumor immunity by sOX40.

View Figures

View References

1	Anari F, Ramamurthy C and Zibelman M: Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol. 14:1409–1421. 2018. View Article : Google Scholar : PubMed/NCBI
2	Huh JW, Lee JH and Kim HR: Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg. 147:366–372. 2012. View Article : Google Scholar : PubMed/NCBI
3	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
4	Teng F, Mu D, Meng X, Kong L, Zhu H, Liu S, Zhang J and Yu J: Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res. 5:2064–2074. 2015.PubMed/NCBI
5	Lee WS, Kang M, Baek JH, Lee JI and Ha SY: Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 20:697–702. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kwak Y, Koh J, Kim DW, Kang SB, Kim WH and Lee HS: Immunoscore encompassing CD3⁺ and CD8⁺ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 7:81778–81790. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yasuda K, Nirei T, Sunami E, Nagawa H and Kitayama J: Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 6:492011. View Article : Google Scholar : PubMed/NCBI
8	Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al: Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 71:5670–5677. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, et al: Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer. 51:2708–2717. 2015. View Article : Google Scholar : PubMed/NCBI
10	Foell J, Hewes B and Mittler RS: T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. Curr Cancer Drug Targets. 7:55–70. 2007. View Article : Google Scholar : PubMed/NCBI
11	Li J and Gu J: Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: A systematic review and meta-analysis. Immunotherapy. 10:1293–1302. 2018. View Article : Google Scholar : PubMed/NCBI
12	Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B and Atallah JP: Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: The era of immunotherapy. Expert Rev Anticancer Ther. 17:47–59. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ishii N, Takahashi T, Soroosh P and Sugamura K: OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 105:63–98. 2010. View Article : Google Scholar : PubMed/NCBI
14	Croft M, So T, Duan W and Soroosh P: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 229:173–191. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gramaglia I, Weinberg AD, Lemon M and Croft M: Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 161:6510–6517. 1998.PubMed/NCBI
16	Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N and Croft M: The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 165:3043–3050. 2000. View Article : Google Scholar : PubMed/NCBI
17	Bansal-Pakala P, Halteman BS, Cheng MH and Croft M: Costimulation of CD8 T cell responses by OX40. J Immunol. 172:4821–4825. 2004. View Article : Google Scholar : PubMed/NCBI
18	Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N and Li XC: OX40 costimulation turns off Foxp3⁺ Tregs. Blood. 110:2501–2510. 2007. View Article : Google Scholar : PubMed/NCBI
19	So T and Croft M: Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25⁺Foxp3⁺ T cells. J Immunol. 179:1427–1430. 2007. View Article : Google Scholar : PubMed/NCBI
20	Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C and Shields J: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 164:2160–2169. 2000. View Article : Google Scholar : PubMed/NCBI
21	Piconese S, Valzasina B and Colombo MP: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 205:825–839. 2008. View Article : Google Scholar : PubMed/NCBI
22	Pan PY, Zang Y, Weber K, Meseck ML and Chen SH: OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 6:528–536. 2002. View Article : Google Scholar : PubMed/NCBI
23	Tanaka Y, Takahashi Y, Tanaka R, Miyagi T, Saito M and Fukushima T: Association of high levels of plasma OX40 with acute adult T-cell leukemia. Int J Hematol. 109:319–327. 2019. View Article : Google Scholar : PubMed/NCBI
24	Weinberg AD, Wegmann KW, Funatake C and Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 162:1818–1826. 1999.PubMed/NCBI
25	Weiss A, Wiskocil RL and Stobo JD: The role of T3 surface molecules in the activation of human T cells: A two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol. 133:123–128. 1984.PubMed/NCBI
26	Hayashi K, Nagasaki E, Kan S, Ito M, Kamata Y, Homma S and Aiba K: Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci. 107:682–689. 2016. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG and MacDonald TT: Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 162:486–493. 1999.PubMed/NCBI
29	Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P and Epstein AL: Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 31:235–245. 2008. View Article : Google Scholar : PubMed/NCBI
30	Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y and Homma S: High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 104:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
31	Weixler B, Cremonesi E, Sorge R, Muraro MG, Delko T, Nebiker CA, Däster S, Governa V, Amicarella F, Soysal SD, et al: OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget. 6:37588–37599. 2015. View Article : Google Scholar : PubMed/NCBI
32	Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS and Levy R: Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 10(pii): eaan44882018. View Article : Google Scholar : PubMed/NCBI
33	Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP and Feldman RM: ICOS promotes the function of CD4⁺ effector T cells during Anti-OX40-mediated tumor rejection. Cancer Res. 76:3684–3689. 2016. View Article : Google Scholar : PubMed/NCBI
34	Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A and Weinberg AD: OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68:5206–5215. 2008. View Article : Google Scholar : PubMed/NCBI
35	Mehrvarz Sarshekeh A, Overman MJ and Kopetz S: Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 14:1869–1874. 2018. View Article : Google Scholar : PubMed/NCBI